Cargando…

Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy

OBJECTIVE: Immunogenicity and safety following receipt of the standard SARS–CoV‐2 vaccination regimen in patients with immune‐mediated inflammatory diseases (IMIDs) are poorly characterized, and data after receipt of the third vaccine dose are lacking. The aim of the study was to evaluate serologic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Syversen, Silje W., Jyssum, Ingrid, Tveter, Anne T., Tran, Trung T., Sexton, Joseph, Provan, Sella A., Mjaaland, Siri, Warren, David J., Kvien, Tore K., Grødeland, Gunnveig, Nissen‐Meyer, Lise S. H., Ricanek, Petr, Chopra, Adity, Andersson, Ane M., Kro, Grete B., Jahnsen, Jørgen, Munthe, Ludvig A., Haavardsholm, Espen A., Vaage, John T., Lund‐Johansen, Fridtjof, Jørgensen, Kristin K., Goll, Guro L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2022
Materias:	COVID‐19
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347774/ https://www.ncbi.nlm.nih.gov/pubmed/35507355 http://dx.doi.org/10.1002/art.42153

Ejemplares similares

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study
por: Christensen, Ingrid Egeland, et al.
Publicado: (2022)

Sa1052: IMMUNOGENICITY AND SAFETY OF STANDARD AND THIRD DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES; A PROSPECTIVE COHORT STUDY
por: Joergensen, Kristin K., et al.
Publicado: (2022)

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
por: Syversen, Silje Watterdal, et al.
Publicado: (2022)

Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
por: Bjørlykke, Kristin H, et al.
Publicado: (2023)

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
por: Jyssum, Ingrid, et al.
Publicado: (2022)

Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosupressive therapy, a prospective cohort study
por: Jorgensen, Kristin, et al.
Publicado: (2022)

A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients
por: Syversen, Silje W, et al.
Publicado: (2008)

Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients
por: Kared, Hassen, et al.
Publicado: (2023)

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
por: Syversen, Silje W, et al.
Publicado: (2020)

Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
por: Brun, Marthe Kirkesæther, et al.
Publicado: (2022)

T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis
por: Wolf, Asia-Sophia, et al.
Publicado: (2023)

Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
por: Tran, Trung The, et al.
Publicado: (2022)

Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
por: Tran, Trung The, et al.
Publicado: (2023)

Course and predictors of work productivity in gout — results from the NOR-Gout longitudinal 2-year treat-to-target study
por: Uhlig, Till, et al.
Publicado: (2023)

The Specificity of Targeted Vaccines for APC Surface Molecules Influences the Immune Response Phenotype
por: Grødeland, Gunnveig, et al.
Publicado: (2013)

Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief
por: Andersen, Tor Kristian, et al.
Publicado: (2021)

Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study
por: Hammer, Hilde Berner, et al.
Publicado: (2022)

Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study
por: Gehin, Johanna Elin, et al.
Publicado: (2019)

Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study
por: Uhlig, Till, et al.
Publicado: (2023)

The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab
por: Provan, Sella Aarrestad, et al.
Publicado: (2015)

Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis
por: Kolan, Shrikant S., et al.
Publicado: (2022)

Humoral vaccine response and breakthrough infections in kidney transplant recipients during the COVID-19 pandemic: a nationwide cohort study
por: Hovd, Markus, et al.
Publicado: (2023)

Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort
por: Gehin, Johanna E., et al.
Publicado: (2021)

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
por: Gehin, Johanna Elin, et al.
Publicado: (2022)

Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults
por: Kared, Hassen, et al.
Publicado: (2022)

Polarizing T and B Cell Responses by APC-Targeted Subunit Vaccines
por: Grødeland, Gunnveig, et al.
Publicado: (2015)

Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis
por: Gehin, Johanna Elin, et al.
Publicado: (2021)

All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study
por: Kerola, Anne M, et al.
Publicado: (2022)

Efficacy of High Intensity Exercise on Disease Activity and Cardiovascular Risk in Active Axial Spondyloarthritis: A Randomized Controlled Pilot Study
por: Sveaas, Silje Halvorsen, et al.
Publicado: (2014)

The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study
por: Provan, Sella A, et al.
Publicado: (2008)

Comparative analyses of responsiveness between the Rheumatoid Arthritis Impact of Disease score, other patient-reported outcomes and disease activity measures: secondary analyses from the ARCTIC study
por: Holten, Karen, et al.
Publicado: (2018)

Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection
por: Zhou, Fan, et al.
Publicado: (2021)

A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza
por: Andersen, Tor Kristian, et al.
Publicado: (2017)

Trimeric, APC-Targeted Subunit Vaccines Protect Mice against Seasonal and Pandemic Influenza
por: Tjärnhage, Elias, et al.
Publicado: (2023)

Prevalence of antibodies against SARS‐CoV‐2 in the Norwegian population, August 2021
por: Tunheim, Gro, et al.
Publicado: (2022)

Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia
por: Holm, Sverre, et al.
Publicado: (2021)

Determinants of humoral and cellular immune responses to three doses of mRNA SARS-CoV-2 vaccines in older adults: a longitudinal cohort study
por: Ravussin, Anthony, et al.
Publicado: (2023)

Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity
por: Søraas, Arne, et al.
Publicado: (2022)

12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target
por: Uhlig, Till, et al.
Publicado: (2021)

One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study
por: Uhlig, Till, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qbk7vr79tj3m3eonn1ootbr1e9